Upregulation of TRPC6 Mediated by PAX6 Hypomethylation Is Involved in the Mechanical Allodynia Induced by Chemotherapeutics in Dorsal Root Ganglion

Xiang-Zhong Zhang, De-Xing Luo, Xiao-Hui Bai, Huan-Huan Ding, Meng Liu, Jie Deng, Jing-Wen Mai, Yan-Ling Yang, Su-Bo Zhang, Xiang-Cai Ruan, Xue-Qin Zhang, Wen-Jun Xin, Ting Xu

The Third Affiliated Hospital, Sun Yet-Sen University, Guangzhou, Guangdong, China (Dr X-Z Zhang and Ms Yang); Department of Anesthesiology, Huizhou Central People’s Hospital, Huizhou, Guangdong, China (Dr Luo and Ms Mai); Department of Anesthesiology, Sun Yat-sen Memorial Hospital (Dr Bai), and Zhongshan School of Medicine, Guangdong Province Key Laboratory of Brain Function and Disease (Ms Ding, Ms Liu, Dr Xin, and Dr Xu), Sun Yat-Sen University, Guangzhou, China; Department of Anesthesia and Pain Medicine, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, China (Mr Deng and Dr Ruan); Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Rehabilitation Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China (Ms S-B Zhang); The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huai Hospital), Guangzhou, China (Dr X-Q Zhang).

Correspondence: Ting Xu, PhD, Department of Physiology and Pain Research Center, Guangdong Province Key Laboratory of Brain Function and Disease, Sun Yat-Sen University, 74 Zhongshan Rd. 2, Guangzhou, China (xuting8@mail.sysu.edu.cn).

X.-Z.Z., D.-X.L., and X.-H.B. contributed equally to this work.

T.X., and S.-B.Z. designed this project and wrote the article together.

Abstract

Background: Although the action mechanism of antineoplastic agents is different, oxaliplatin, paclitaxel, or bortezomib as first-line antineoplastic drugs can induce painful neuropathy. In rodents, mechanical allodynia is a common phenotype of painful neuropathy for 3 chemotherapeutics. However, whether there is a common molecular involved in the different chemotherapeutics-induced painful peripheral neuropathy remains unclear.

Methods: Mechanical allodynia was tested by von Frey hairs following i.p. injection of vehicle, oxaliplatin, paclitaxel, or bortezomib in Sprague-Dawley rats. Reduced representation bisulfite sequencing and methylated DNA immunoprecipitation were used to detect the change of DNA methylation. Western blot, quantitative polymerase chain reaction, chromatin immunoprecipitation, and immunohistochemistry were employed to explore the molecular mechanisms.

Results: In 3 chemotherapeutic models, oxaliplatin, paclitaxel, or bortezomib accordantly upregulated the expression of transient receptor potential cation channel, subfamily C6 (TRPC6) mRNA and protein without affecting the DNA methylation level of TRPC6 gene in DRG. Inhibition of TRPC6 by using TRPC6 siRNA (i.t., 10 consecutive days) relieved mechanical
Significance Statement

Activation of PAX6/TRPC6 in DRG neurons may be a common signal pathway for mechanical allodynia following oxaliplatin, paclitaxel, or bortezomib application. A DNA hypomethylation-mediated epigenetic mechanism in the PAX6 gene contributed to the upregulation of the PAX6/TRPC6 pathway. Targeted on PAX6/TRPC6, signaling may provide a new idea and reliable basis for the treatment of different chemotherapeutics-induced chronic pain.

Introduction

In spite of their different antitumor mechanisms, any one of the chemotherapeutic drugs oxaliplatin, paclitaxel, or bortezomib causes painful neuropathy (Liu et al., 2016; Xu et al., 2017; Meng et al., 2019). Clinically, the manifestation of painful neuropathy is varied, including tingling, loss of proprioception sense, burning pain, etc. (Haythornwaite and Benrud-Larson, 2003; Brandolini et al., 2019). Similar to clinical manifestations, painful neuropathy is manifested in various forms in rodent models. Among these symptoms, mechanical allodynia is a common phenotype with oxaliplatin, paclitaxel, or bortezomib (Laumet et al., 2015; Huang et al., 2016; Stockstill et al., 2018). Studies showing that transient receptor potential cation channel subfamily V member 1 (TRPV1) play an important role in the burning pain in humans (Simone et al., 1989; Li et al., 2015) and thermal hyperalgesia in rats (Hara et al., 2013) suggested that TRPV1 may be a key ion channel mediating thermal pain. However, it remains unclear whether there is a common ion channel involved in the mechanical allodynia induced by different chemotherapeutic agents.

The excitability of DRG neurons is fundamentally determined by the functional activities of neuronal ion channels in various conditions of chronic pain. For example, the change of sodium channel, calcium channel, or other ion channel in DRG is involved in the chronic pain induced by nerve injury or inflammation (Fischer et al., 2017; Sakai et al., 2017; Shan et al., 2019). Mammalian transient receptor potential (TRP) channel proteins can be classified into 6 subfamilies: TRPC, TRPV, TRPM, TRPA, TRP, and TRPML (Ramsey et al., 2006). The TRP cation channel, subfamily C (TRPC) consists of 7 members (TRPC1–7) and serves a wide range of physiological functions ranging from proliferation of cells to mechanical sensory transduction (Nakao et al., 2015). Among them, TRPC6 upregulation contributed to chronic morphine-induced hyperalgesia (Jin et al., 2017). Furthermore, TRPC6 is also involved in the mechanical allodynia induced by inflammatory or diabetes (Alessandri-Haber et al., 2009; Roa-Coria et al., 2019). Whether TRPC6 is a common molecular to mediate the mechanical allodynia induced by different chemotherapeutics remains unclear. Studies have shown that epigenetic mechanisms such as DNA methylation play an important role in chronic pain through regulating target protein expression (Anis and Mosek, 2018; Louwies et al., 2019). However, whether DNA methylation is involved in TRPC6 expression is unknown.

PAX6, as a member of the paired box family, plays a critical role in brain development (Walther and Gruss, 1991; Wallimann and Rink, 2001). For example, PAX6 regulates the proliferation of neural stem mediate autism spectrum disorder (Kikkawa et al., 2019). As a conserved transcription factor with 2 different DNA-binding domains, PAX6 also mediates both embryonic and adult neurogenesis (Osumi et al., 2008). Furthermore, a recent study showed that adult spinal cord neurogenesis via increasing neuronal excitability contributed to chronic pain (Rusanescu, 2016). However, to date, no evidence to our knowledge has shown that PAX6 in DRG neurons is involved in chronic pain. In addition, as a transcription factor, whether PAX6 mediates TRPC6 expression remains unclear.

Materials and Methods

Animals

Male Sprague-Dawley rats weighing 200 to 220 g were obtained from the Institute of Experimental Animals of Sun Yat-sen University and housed in a temperature- and humidity-controlled room (50–60% humidity, 22°C ± 1°C) on a 12-h-light-/dark cycle. Animals were housed in separated cages with ad libitum access to food and water. All experimental protocols were approved by the Animal Care and Use Committee of Sun Yat-sen University and were carried out in accordance with the guidelines of the National Institutes of Health on animal care and ethical guidelines.

Animals were randomly assigned to the experimental groups. Each group included more than 3 animals, and the specific number of animals in each group is indicated in the figure legends. All data were collected and analyzed by 2 independent observers who were blinded to the group assignment of the animals or the treatment group during analysis.

Drug Application and Behavioral Test

Oxaliplatin (4 mg/kg, Sigma Aldrich, St. Louis, MO), paclitaxel (8 mg/kg, Bristol-Myers Squibb, New York City, NY), and bortezomib (0.2 mg/kg, Haoran Biological Technology Co., Shanghai, China) were prepared before each treatment and injected i.p. Oxaliplatin or bortezomib was i.p. injected once a day.
for 5 consecutive days, and paclitaxel was injected once a day on days 1, 4, and 7.

TRPC6 siRNA, PAX6 siRNA, or scramble siRNA (1 nmol, 10 μL, once a day) was injected intrathecally for 10 consecutive days. Intrathecal injection was in accordance with the previous method (Xu et al., 2017). In brief, a polyethylene-10 catheter was inserted into the L5/L6 intervertebral subarachnoid space of the rat following the injection of sodium pentobarbital (50 mg/kg, i.p.), and the localization of the catheter tip was placed at the L5 spinal segmental level. After 5 days of recovery, 5 rats with hind limb paralysis or paresis after surgery were excluded from the study.

The 50% paw withdrawal threshold was assessed using von Frey hairs (Ugo Basile, Gemonio, Varese, Italy) according to our and peer’s previous reports (Chaplan et al., 1994; Xu et al., 2017). In short, each animal was loosely restrained in a plastic box and allowed to adapt for at least 15 minutes per day for 3 consecutive days before testing. Then, series of von Frey filaments with different bending force were presented to the mid-plantar surface of each hind paw. In the absence of a paw withdrawal response to the initially selected hair, a stronger stimulus was presented; in the event of paw withdrawal, the next weaker stimulus was chosen. Optimal threshold calculation by this method required 6 responses in the immediate vicinity of the 50% threshold.

**qPCR (Real-time Quantitative PCR Detecting System) and qPCR Array**

Under anesthesia using sodium pentobarbital, L4 to L6 DRGs in rats were isolated, and TRIzol reagent (Invitrogen, Carlsbad, CA) was used to extract total RNA. The reverse transcription and qPCR were performed with Prime Script RT Master Mix (Takara Bio Inc., Kusatsu, Shiga, Japan). Real-time quantitative polymerase chain reaction (qPCR) was performed with SYBR Premix Ex TaqII (Takara). The relative expression ratio of mRNA expression was determined with a BCA protein assay (ThermoFisher Scientific). The protein samples were separated via gel electrophoresis and transferred onto a polyvinylidene fluoride membrane. The membranes were incubated in a primary antibody against TRPC6 (1:200, Alomone Labs, Jerusalem, Israel), PAX6 (1:500, Abcam, Cambridge, UK), DNMT3b (1:500, Abcam), β-actin (1:1000, CST, Boston, MA), and histone H3 (1:1000, Abcam) overnight at 4°C. Horseradish peroxidase-conjugated secondary antibodies were used to incubate the blots. Enhanced chemiluminescence solution (Pierce) was used to detect immunocomplexes. Each band was quantified using a computer-assisted imaging analysis system (NIH Image).

**Immunohistochemistry**

Perfusion was performed through the ascending aorta with 4% paraformaldehyde after application of sodium pentobarbital (50-mg/kg dose, i.p.). The removed DRGs were placed into 4% paraformaldehyde for post fixing overnight. Cryostat sections of 16-μm thickness were obtained, and immunohistochemistry was performed with primary antibodies for TRPC6 (1:100; Alomone Labs), PAX6 (1:200; Abcam), NF200 (1:200; Chemicon), IB4 (1:50; Sigma Aldrich), and GFAP (1:400; CST). After overnight incubation at 4°C, the sections were incubated with secondary antibodies, which conjugated with cy3 or Alexa488-fluorescein isothiocyanate for 1 hour at room temperature. A Nikon (Nikon Eclipse Ni-E, Japan) confocal microscopy was used to examine the fluorescence of tissue slices.

**Reduced Representation Bisulfite Sequencing**

Genomic DNA was extracted from DRG of 10 days after chemotherapeutic drug group or vehicle group using the QIAamp DNA Micro Kit (Qiagen, 56 304). Reduced representation bisulfite sequencing (RRBS) sequencing libraries were prepared as describe previously (Gu et al., 2011). Briefly, a total amount of 5.2 μg genomic DNA spiked with 26 ng lambda DNA was fragmented by sonication to 200 to 300 bp with Covaria S220 followed by end repair and adenylation. Cytosine-methylated barcodes were ligated to sonicated DNA as per manufacturer’s instructions. Furthermore, these DNA fragments were treated twice with bisulfite using an EZ DNA Methylation-Gold Kit (Zymo Research) before the resulting single-strand DNA fragments were PCR amplified using KAPA HiFi HotStart Uracil + ReadyMix (2X). Qubit 2.0 Fluorometer (Life Technologies, CA) and qPCR were used to quantify library concentration, and the insert size was assayed on an Agilent Bioanalyzer 2100 system. Then the library preparations were sequenced on an Illumina Hiseq 2500/4000 or Novaseq platform, and 125-bp/150-bp paired-end reads were generated. Finally, image analysis and base calling were performed with Illumina CASAVA pipeline, and 125-bp/150-bp paired-end reads were generated.

**Methylated DNA Immunoprecipitation Assay**

Rats were deeply anesthetized with sodium pentobarbital (50-mg/kg dose, i.p.), and then the L4-L6 DRGs were rapidly harvested. The Methylated DNA Immunoprecipitation (MeDIP) methods were used to quantify methylation changes in specific DNA regions of PAX6 and IRX5. In short, genomic DNA extracted from DRG was sheared into random fragments using ultrasound instrument Bioruptor and then incubated with monoclonal 5-methylcytosin antibody overnight at 4°C. Magnetic beads conjugated to anti-mouse-IgG are used to bind the anti-5mC antibodies, and the precipitate was

### Table 1. Specific Primer Sequences for qPCR

| Gene       | Primer     | Sequence                  |
|------------|------------|---------------------------|
| TRPC6 (Rat)| Forward    | 5′-GGCGGACAGCAGTTCTCGTGAG-3′ |
|            | Reverse    | 5′-CTTCTAGCACTTCCGCGACCTG-3′ |
| DNMT1 (Rat)| Forward    | 5′-GACCAATGAGGACACTGCG-3′ |
|            | Reverse    | 5′-GACCGGAGTCGGATACACA-3′ |
| DNMT3a (Rat)| Forward   | 5′-GGCGGGACAGCTGCTGGTA-3′ |
|            | Reverse    | 5′-CTTGCTATCTCCTGCAGTTC-3′ |
| DNMT3b (Rat)| Forward   | 5′-GATGATCGAGGCGCATCAAG-3′ |
|            | Reverse    | 5′-GCAGCTTATCATCTTGGAAGCT-3′ |
| PAX6 (Rat) | Forward    | 5′-CAGAGTTCTCTGGAACCTGCTAG-3′ |
|            | Reverse    | 5′-GGTCCTGGGTCGTCATCCTTAG-3′ |
| β-actin (Rat)| Forward | 5′-AGGGAAAATCGTGGTGCAAT-3′ |
|            | Reverse    | 5′-GAACGAGTCATTGGCGATAG-3′ |
rinsed with elution buffer (50 mM Tris-HCl, pH = 8.0; 10 mM EDTA, pH = 8.0; 1% SDS). DNA was purified with phenol-chloroform solution (phenol to chloroform to isoamyl alcohol = 25:24:1) and collected. Finally, qPCR was used to test the expression of PAX6- and IRX5-specific regions. The primer sequences are listed in Table 2.

### Chromatin Immunoprecipitation Assay

The kit (ThermoFisher Scientific) was used to perform chromatin immunoprecipitation (ChIP) assays. The rats’ L4-L6 DRGs were isolated and placed in 1% formaldehyde for 2 minutes. Sonication was applied to DNA fragments and subsequently digested by micrococcal nuclease. Samples (100 μL) were saved as input after the addition of ChIP dilution buffer. PAX6 antibody or DNMT3b antibody was added to 500 μL for pre-clearing, and then the samples were incubated overnight. Immunoprecipitation with control mouse IgG (Sigma Aldrich) was performed as a negative control. The DNA was purified from the DNA/antibody complexes through elution and reversion. qPCR was applied on 5 μL of precipitated DNA samples. The primers projected to amplify the specific regions of TRPC6 were listed in Table 3. Finally, the ChIP to input ratio was calculated.

### siRNA Preparation and Screening

Specific siRNAs were applied to knockdown the expression of TRPC6 and PAX6 in a targeted fashion as previously described (Xu et al., 2017). Scramble siRNA without any gene homology was used as a negative control. Briefly, siRNAs designed and synthesized by Ribobio (Guangzhou, China) were first transfected into the HBZY-1 cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). TRPC6 and PAX6 expression levels were significantly inhibited by detecting qPCR (data not shown). Our pilot in vivo experiments showed that intrathecal injection of TRPC6 siRNA or PAX6 siRNA also remarkably suppressed the expression of mRNA and protein expression in DRG of rats (data not shown). The nucleotide sequences of TRPC6 and PAX6 siRNA were shown in Table 4.

### Statistical Analysis

All data were expressed as means ± SEM. The results from the behavioral tests, western blot, or qPCR were statistically analyzed with 1-way or 2-way (repeated-measures) ANOVA followed by Bonferroni post hoc test. The criterion for statistical significance was P < .05. Statistical tests were performed with SPSS 25.0 (IBM SPSS).

## Results

### Upregulation of TRPC6 in DRG Neurons Contributed to Mechanical Allodynia Induced by Oxaliplatin, Paclitaxel, or Bortezomib Treatment

Consistent with the previous studies (Liu et al., 2016; Xu et al., 2017; Zhang et al., 2018), the mechanical withdrawal threshold of rats was markedly decreased after i.p. administration of oxaliplatin (4 mg/kg once a day for consecutive 5 days), paclitaxel (3 × 8 mg/kg, once a day on days 1, 4, and 7), or bortezomib (0.2 mg/kg once a day for consecutive 5 days). The mechanical allodynia occurred on day 5 and persisted to day 15 (experiment ended) after chemotherapeutics injection (Figure 1A). The common phenotype and similar time course raised a hypothesis maybe there is a common molecule that mediates mechanical allodynia caused by three different chemotherapeutics in DRG. So we examined the mRNA expression of all ion channels in rats’ DRGs by using PCR array. TRPC6 is the only molecular that is significantly upregulated in on 5 and day 15 after all 3 chemotherapeutics treatment (Figure 1B; supplementary Table 1). The results of qPCR and western blot further verified that application of oxaliplatin, paclitaxel, or bortezomib evidently enhanced the mRNA (Figure 1C) and protein (Figure 1D–F) levels of TRPC6 in DRG. Double immunofluorescent staining revealed that TRPC6 was primarily expressed in NF200-positive and IB4-positive neurons but not in GFAP-positive satellite glial cells (Figure 1–G1–I). Importantly, knockdown of TRPC6 by intrathecal injection of TRPC6 siRNA for 10 consecutive days significantly inhibited the mechanical allodynia induced by oxaliplatin, paclitaxel, or bortezomib (Figure 1J–L). Collectively, these results suggested that TRPC6 may be a common molecular mediating chronic pain induced by different chemotherapeutic agents in DRG.

### Chemotherapeutic Treatment Enhanced the DNA Methylation Level of PAX6 Gene

Studies have shown that DNA methylation-mediated epigenetic mechanisms play an important role in neuropathic pain, and DNA methylation is exclusively found in CpG dinucleotides in mammals. To determine whether DNA methylation is involved in the upregulation of TRPC6, we first observed the methylation change in TRPC6 loci following the oxaliplatin treatment by using RRBS. The results revealed that the methylation level of TRPC6 loci did not change, although the methylation level in TRPC6 loci did not change, 1045 differentially methylated regions (DMRs) on chromosomes were observed following the oxaliplatin treatment (Figure 2B). These DMRs were mapped to 811 genes, and Gene Ontology analysis showed that 80 of these genes were closely related with the nervous system development biological process (Figure 2C; Table 2).

## Table 2. Specific Primer Sequences for MeDIP

| Gene (Rat) | Primer | Sequence   |
|------------|--------|------------|
| PAX6       | Forward| 5′- CCAAATCCTGCAAATCTATACC -3′ |
|            | Reverse| 5′- GCTGGACTGAGATTGACTAGG -3′  |
| IRX5       | Forward| 5′- TTCTATCCGGCCTCACAGGAAC -3′ |
|            | Reverse| 5′- TCGCGACAGATTCAAACCGGC -3′  |

## Table 3. Specific Primer Sequences for ChIP

| Gene (Rat) | Primer | Sequence   |
|------------|--------|------------|
| TRPC6      | Forward| 5′- AACACAGAAGCGCTTTCATTT -3′ |
|            | Reverse| 5′- AACACCTGGAGCAAGGCGTC-3′  |
| PAX6       | Forward| 5′- CCAAATCCTGAAATCTATACC -3′ |
|            | Reverse| 5′- GCTGGACTGAGATTGACTAGG -3′  |

## Table 4. Nucleotide Sequences of TRPC6 and PAX6 siRNA

| Gene (Rat) | Primer | Sequence           |
|------------|--------|--------------------|
| TRPC6      | Rat    | 5′- GCUCAACAGAUAUU CCAUUU dTdT -3′ (sense) |
|            | Rat    | 5′- AAAUGGAAAAACUUCUGACG dTdT -3′ (antisense) |
| PAX6       | Rat    | 5′- UUCACAGAAGAGGACCC dTdT -3′ (sense) |
|            | Rat    | 5′- UUGCUGAAACACUCUGAGG dTdT -3′ (antisense) |
Figure 1. Upregulation of TRPC6 in DRG neurons contributed to mechanical allodynia induced by 3 chemotherapeutics. (A) The hind paw withdraw threshold of rats was obviously reduced following oxaliplatin, paclitaxel, or bortezomib treatment (n = 12 in each group; *P < .05, **P < .01 vs the vehicle group). (B) The heatmap of PCR array showed the relative mRNA expression of 84 ion channels in DRG following chemotherapeutics treatment (n = 4 in each group). (C–F) The levels of TRPC6 mRNA (C) and protein (D–F) in DRG were significantly upregulated following chemotherapeutics treatment (n = 4 in each group; **P < .01 vs the vehicle group). (G–I) The immunofluorescence staining showed the colocalization of TRPC6 (red) with NF200 (a marker for A-type neurons, green) and IB4 (a marker for C-type neurons), but not GFAP (a marker for satellite glial cells, green) in DRG (n = 4 in each group), scale bar = 100 μm. (J–L) Intrathecal injection of TRPC6 siRNA for 10 consecutive days obviously relieved the mechanical allodynia in rats treated with oxaliplatin, paclitaxel, or bortezomib (n = 12 in each group; *P < .05, **P < .01 vs the vehicle group; #P < .05, ##P < .01 vs the chemotherapeutics group). BTZ, Bortezomib; Oxal, Oxaliplatin; Pacl, Paclitaxel; Veh, Vehicle.
supplementary Table 2). It is well known that transcription factors play an important role in the target protein expression, so we hypothesize that upregulation of transcription factors mediated by the change of methylation may be involved in the increase of TRPC6 following chemotherapeutic drug treatment. By using Genomatix database analysis, we predicted 50 nervous system-related transcription factors closely related to TRPC6 expression (supplementary Table 3). We integrated the analysis of Gene Ontology and Genomatix database and screened 4 transcription factors with potential binding sites to TRPC6 promoter (Figure 2D). Of the 4 transcription factors, PAX6 and iroquois homeobox 5 (IRX5) showed more significant difference of methylation and were chosen for the subsequent study (Figure 2D). Furthermore, we explored the methylation level of DMR in PAX6 or IRX5 by using the anti-5-mc–mediated MeDIP assay. The results showed that the methylation level of PAX6 DNA, but not IRX5 DNA, containing the DMR (chr3: 330−440 for PAX6 and chr19: 4365−4481 for IRX5) decreased significantly following oxaliplatin, paclitaxel, or bortezomib treatment (Figure 2E–G). These results implied that the hypomethylation of transcription factor PAX6 gene may be a common signal event induced by different chemotherapeutic agents.

Chemotherapeutics Treatment Decreased the Recruitment of DNMT3b on PAX6 Gene

It is well known that DNA methyltransferases (DNMT), including DNMT1, DNMT3a, and DNMT3b, via translocating into the nucleus contributed to the DNA methylation in mammals (Ventham et al., 2013; Day et al., 2015; Norollahi et al., 2019). To understand the mechanism underlying the hypomethylation of PAX6 gene, we first explored the expression of all DNMT mRNA following chemotherapeutics treatment. The results showed that the mRNA level of DNMT3b, but not DNMT1 or DNMT3a, was markedly decreased on day 5 and day 15 following chemotherapeutics injection (Figure 3A–C). Furthermore, the level of DNMT3b protein in nuclei was significantly decreased following the chemotherapeutics treatment compared with the vehicle group (Figure 3D–F). Importantly, ChIP-PCR assay showed that the recruitment of DNMT3b at DMR of PAX6 gene (+330 − +440) was significantly downregulated after all 3 chemotherapeutics treatments, respectively (Figure 3G–I). These results suggested that chemotherapeutics via decreased levels of nucleus DNMT3b downregulated the recruitment of DNMT3b at the PAX6 gene.

Enhanced Expression of PAX6 in DRG Neurons Involved in Mechanical Allodynia Induced by Chemotherapeutics

Previous study has established that DNA hypomethylation via promoting target gene transcription mediated the target protein upregulation (Ozaki et al., 2017). Here, qPCR and western-blot analysis revealed that chemotherapeutics treatment significantly upregulated the expression of PAX6 mRNA (Figure 4A) and protein (Figure 4B–D) in the DRG on day 5 and day 15. The double immunostaining showed that PAX6 was primarily expressed in NF200-positive and IB4-positive cells, but not GFAP-positive cells (Figure 4E). Importantly, intrathecal injection of PAX6 siRNA for 10 continuous days markedly attenuated the mechanical allodynia induced by oxaliplatin (Figure 4F), paclitaxel (Figure 4G), or bortezomib (Figure 4H) treatment. These results demonstrated that the increased expression of PAX6 in DRG neurons participated in mechanical allodynia induced by chemotherapeutics.

**Figure 2.** The change of PAX6 gene methylation level followed chemotherapeutics treatment. (A) RRBS results showed the change of methylation level in TRPC6 loci before and after oxaliplatin treatment. (B) Circos diagram showed DMRs distributed globally across all chromosomes. (C) The Gene Ontology (GO) pathway analysis showed the enrichment degree of biological process with differential DMR mapped genes. (D) Venn diagram showed the overlap of genes between GO analysis and Genomatix database. (E-G) MeDIP assay was performed to detect the change of DNA methylation level in specific regions of PAX6 and IRX5 loci after chemotherapeutics treatment for 15 days in DRG (n = 3 in each group; *P < .05, **P < .01 vs the correspondence vehicle group). BTZ, Bortezomib; IR, IRX5; Oxal, Oxaliplatin; PA, PAX6; TFs, Transcription factors; Veh, Vehicle.
PAX6 Contributed to Upregulation of TRPC6 Following Chemotherapeutics Treatment

Next, we further validated whether the upregulated transcription factor PAX6 mediated the TRPC6 expression following chemotherapeutics treatment. Double immunostaining showed that the expression of PAX6 was colocalized with TRPC6-positive cells in DRG (Figure 5A). Intrathecal injection of PAX6 siRNA for 10 consecutive days obviously prevented the upregulation of TRPC6 protein in DRG on day 15 following chemotherapeutics treatment (Figure 5B–D). Next, TFSEARCH and JASPAR database analysis showed that the position of TRPC6 (−636/−625) is a potent binding site for PAX6. The DNA, precipitated by the PAX6 antibody, was subjected to PCR to amplify a 128-bp fragment (−727/−600) of the TRPC6 promoter, which contained the PAX6-binding site with the designed primers. ChIP-qPCR analysis revealed that the recruitment of PAX6 to the TRPC6 promoter was markedly increased on day 15 after application of chemotherapeutics relative to the vehicle group. Importantly, the enhanced binding between PAX6 and TRPC6 promoter was decreased in rats with application of PAX6 siRNA following chemotherapeutic treatment (Figure 5E–G).

Discussion

It has been suggested that ion channels in DRG neurons are involved in the neuropathic pain following nerve injury or inflammatory (Lin et al., 2016; Mao et al., 2017). TRP channels have a physiological role in the mechanisms controlling several physiological responses like temperature and mechanical sensations (Marwaha et al., 2016). For example, heat activates TRPVs (Guler et al., 2002; Hong and Wiley, 2005), while cold temperatures ranging from affable to painful activate TRPA1 and TRPM8 (McKemy et al., 2002; Story et al., 2003). Among TRPC
channels, a recent study showed that the spinal TRPC6 channel contributes to morphine-induced hyperalgesia (Jin et al., 2017). In the present study, qPCR array analysis first showed that application of 3 chemotherapeutic drugs with different antitumor mechanisms only upregulated the expression of TRPC6 in DRG neurons. Inhibition of TRPC6 by intrathecal injection of TRPC6 siRNA attenuated the mechanical allodynia induced by 3 chemotherapeutics. These results first indicated that TRPC6 upregulation in DRG neurons participated in different chemotherapeutic-induced mechanical allodynia. This result is similar with that TRPC6 is involved in the mechanical hyperalgesia induced by inflammatory or nerve injury (Alessandri-Haber et al., 2009; Roa-Coria et al., 2019). While the possibility existed that the analgesia induced by intrathecal dosing scheme in the present study might be partially supplemented with its potential effect on spinal cord, our results at least showed that the TRPC6 in DRG might be a common therapeutic target for mechanical allodynia induced by chemotherapeutics.

In the current study, we further found that the expression of TRPC6 increased following chemotherapeutic treatment. Given that DNA methylation plays a critical role in the enhancement of target gene transcription, we examined the change of the DNA methylation level of TRPC6. Unexpectedly, the methylation level of TRPC6 loci was not affected following oxaliplatin.

Figure 4. Increased expression of PAX6 in DRG neurons was involved in mechanical allodynia induced by 3 chemotherapeutics. (A) The expression of PAX6 mRNA was significantly increased following oxaliplatin, paclitaxel, or bortezomib treatment (n = 6 in each group; **P < .01 vs the vehicle group). (B–D) Representative blots and histograms showed the total expression of PAX6 protein after chemotherapeutics treatment (n = 4 in each group; *P < .05, **P < .01 vs the vehicle group). (E) The immunofluorescence staining showed the colocalization of PAX6 (red) with NF200 (a marker for A-type neurons, green) and IB4 (a marker for C-type neurons), but not GFAP (a marker for satellite glial cells, green) in DRG (n = 4 in each group), scale bar = 100 μm. (F–H) Intrathecal injection of PAX6 siRNA obviously attenuated the mechanical allodynia induced by oxaliplatin, paclitaxel, or bortezomib (n = 12 in each group; *P < .05, **P < .01 vs the vehicle group, #P < .05, ##P < .01 vs the corresponding chemotherapeutics group). BTZ, Bortezomib; Oxal, Oxaliplatin; Pacl, Paclitaxel; Veh, Vehicle.
treatment. Studies showed that upregulation and transloca-
tion of the transcriptional factor into the nucleus is a canonical
way to regulate target gene expression. Furthermore, we found
that 80 genes with methylation changes are mainly enriched
on the nervous system biological process. Integrated with bio-
informatics analysis, PAX6 may be a key transcriptional factor
for TRPC6 upregulation, as PAX6 is fit for these criteria that
hypomethylation of PAX6 loci and can bind to TRPC6 promotor
as a transcription factor. To prove this hypothesis, we first ob-
served the role of PAX6 in the mechanical allodynia. The re-
results showed that chemotherapeutic treatment increased
PAX6 expression and local suppression of TRPC6 by using
siRNA ameliorated mechanical allodynia. Although evidence
showed that PAX6 plays a key role in neurogenesis, which
contributed to hyperalgesia in the spinal cord (Rusanescu,
2016), the present study is the first time to testify that PAX6
DRG neurons participated in the chronic pain induced by
chemotherapeutics. As a transcriptional factor, PAX6 regulated
target gene expression by binding to the promoter (Cvekl et al.,
2004). Here, we also found that chemotherapeutics increased
the binding between PAX6 and TRPC6 promoter and applica-
tion of PAX6 siRNA attenuated the interaction. Moreover, the

Figure 5. Increased PAX6 mediated TRPC6 upregulation in DRG neurons following chemotherapeutics treatment. (A) The double immunofluorescence staining indicated colocalization of PAX6 with TRPC6 in DRG neurons of rats (n=4 in each group), scale bar = 100 μm. (B–D) Intrathecal injection of PAX6 siRNA significantly prevented the chemotherapeutics-induced TRPC6 upregulation (n=6 in each group, **P<.01 vs the vehicle group, ###P<.01 vs the corresponding chemotherapeutics group). (E–G) Following PAX6 siRNA application (i.t.), ChIP assay was performed with PAX6 antibody on day 15 after chemotherapeutics treatment in rats (n=3 in each group, **P<.01 vs the vehicle group, ###P<.01 vs the corresponding chemotherapeutic group). BTZ, Bortezomib; Oxal, Oxaliplatin; Pacl, Paclitaxel; Veh, Vehicle.
increased PAX6 mRNA resulted from the hypomethylation of PAX6 loci mediated by DNMT3b, because the expression of DNMT3b and its binding with PAX6 gene were significantly decreased after application of chemotherapeutics. Up to now, the results first showed that DNMT3b is involved in the hypomethylation of PAX6, suggesting that inhibition of DNMT3b-mediated hypomethylation of PAX6 in DRG might be a novel therapy target for chronic pain.

In conclusion, our study revealed that the activation of PAX6/TRPC6 in DRG neurons may be a common signal pathway for mechanical allodynia following 3 chemotherapeutics application. Furthermore, hypomethylation-mediated epigenetic mechanisms in PAX6 gene might have contributed to the upregulation of the PAX6/TRPC6 pathway. So focusing on PAX6/TRPC6 signaling may provide new ideas and a reliable basis for the treatment of different chemotherapeutics-induced chronic pain.

Supplementary Materials
Supplementary data are available at International Journal of Neuropsychopharmacology (IJNPPY) online.

Acknowledgments
The authors are entirely responsible for the scientific content of the article.

This study was supported by the National Natural Science Foundation of China (no. 81801103), the China Postdoctoral Science Foundation (nos. 2018M631019 and 2019T120767), the Fundamental Research Funds for the Central Universities (No. 18ykpy41), the Guangzhou Innovation Platform construction Project (No. 2060404), the Natural Science Foundation of Guangdong Province (2019A1515010871), and the 111 Project (No. B13037).

Statement of Interest
None.

References
Alessandri-Haber N, Dina OA, Chen X, Levine JD (2009) TRPC1 and TRPC6 channels cooperate with TRPV4 to mediate antinociceptive and nociceptor sensitization. J Neurosci 29:6217–6228.
Anis S, Mosek A (2018) [Epigenetic mechanisms in models of chronic pain - a target for novel therapy?]. Harefuah 157:370–373.
Brandolini L, d’Angelo M, Antonosante A, Allegretti M, Cimini A (2017) Effect of paclitaxel on transient receptor potential vanilloid 1 in rat dorsal root ganglion. Pain 154:882–889.
Haythornthwaite JA, Benrud-Larson LM (2001) Psychological assessment and treatment of patients with neuropathic pain. Curr Pain Headache Rep 5:124–129.
Hong S, Wiley JW (2005) Early painful diabetic neuropathy is associated with differential changes in the expression and function of vanilloid receptor 1. J Biol Chem 280:616–627.
Huang ZZ, Li D, Ou-Yang HD, Liu CC, Liu XG, Ma C, Wei JY, Liu Y, Xin WJ (2016) Cerebrospinal fluid oxaliplatin contributes to the acute pain induced by systemic administration of oxaliplatin. Anesthesiology 124:1109–1121.
Jin H, Sun YT, Guo QQ, Chen DL, Li YJ, Xiao GP, Li XN (2017) Spinal TRPC6 channels contribute to morphine-induced antinociceptive tolerance and hyperalgesia in rats. Neurosci Lett 639:138–145.
Kikkawa T, Casingal CR, Chun SH, Shinohara H, Hiraoka K, Osumi N (2019) The role of Pax6 in brain development and its impact on pathogenesis of autism spectrum disorder. Brain Res 1705:95–103.
Laumet G, Garriga J, Chen SR, Zhang Y, Li DP, Smith TM, Dong Y, Jelinek J, Cesaroni M, Issa JP, Pan HL (2015) G9a is essential for epigenetic silencing of K(+) channel genes in acute-to-chronic pain transition. Nat Neurosci 18:1746–1755.
Li Y, Adamek P, Zhang H, Tatsui CE, Rhines LD, Mrozova P, Li Q, Kosturakis AK, Cassidy RM, Harrison DS, Cata JP, Sapire K, Zhang H, Kennamer-Chapman RM, Jawad AB, Ghetti A, Yan J, Pacecek J, Dougherty PM (2015) The cancer chemotherapeutic paclitaxel increases human and rodent sensory neuron responses to TRPV1 by activation ofTLR4. J Neurosci 35:13487–13500.
Lin SF, Yu XL, Wang B, Zhang YJ, Sun YG, Liu XJ (2016) Colocalization of insulin-like growth factor-1 receptor and T type Cav3.2 channel in dorsal root ganglia in chronic inflammatory pain mouse model. Neuroreport 27:737–743.
Liu C, Luan S, OuYang H, Huang Z, Wu S, Ma C, Wei J, Xin W (2016) Upregulation of CCL2 via ATF3/c-Jun interaction mediated the bortezomib-induced peripheral neuropathy. Brain Behav Immun 53:96–104.
Louwies T, Ligon CO, Johnson AC, Greenwood-Van Meerveld B (2019) Targeting epigenetic mechanisms for chronic visceral pain: a valid approach for the development of novel therapeutics. Neurogastroenterol Motil 31:e13500.
Mao Q, Yuan J, Ming X, Wu S, Chen L, Bekker A, Yang T, Tao YX (2017) Role of dorsal root ganglion K2p1.1 in peripheral nerve injury-induced neuropathic pain. Mol Pain 13:1744806917701135.
Marwaha L, Bansal Y, Singh R, Saroj P, Bhandari R, Kuhad A (2016) TRP channels: potential drug target for neuropathic pain. Inflammopharmacology 24:305–317.
McKemy DD, Neuhauser WM, Julius D (2002) Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 416:52–58.
Meng J, Zhang Q, Yang C, Xiao L, Xue Z, Zhu J (2019) Duloxetine, a balanced serotonin-norepinephrine reuptake inhibitor, improves painful chemotherapy-induced peripheral neuropathy by inhibiting activation of p38 MAPK and NF-κB. Front Pharmacol 10:365.

Nakao K, Minato N, Uemoto S (2015) Innovative medicine: basic research and development. Tokyo: Springer.

Nie B, Liu C, Bai X, Chen X, Wu S, Zhang S, Huang Z, Xie M, Xu T, Xin W, Zeng W, Ouyang H (2016) AKAP150 involved in paclitaxel-induced neuropathic pain via inhibiting CN/NFAT2 pathway and downregulating IL-4. Brain Behav Immun 68:158–168.

Norollahi SE, Mansour-Ghanaei F, Joukar F, Ghadarjani S, Mojtahedi K, Gharaii Nejad K, Hemmati H, Gharibpoor F, Khakzar R, Samadani AA (2019) Therapeutic approach of cancer stem cells (CSCs) in gastric adenocarcinoma; DNA methyltransferases enzymes in cancer targeted therapy. Biomed Pharmacother 115:108958.

Osumi N, Shinohara H, Numayama-Tsuruta K, Maekawa M (2018) Concise review: Pax6 transcription factor contributes to both embryonic and adult neurogenesis as a multifunctional regulator. Stem Cells 26:1663–1672.

Ozaki Y, Yoshino Y, Yamazaki K, Sato T, Mori Y, Ochi S, Yoshida T, Mori T, Iga JI, Ueno SI (2017) DNA methylation changes at TREM2 intron 1 and TREM2 mRNA expression in patients with Alzheimer’s disease. J Psychiatr Res 92:74–80.

Rusanescu G (2016) Adult spinal cord neurogenesis: a regulator of nociception. Neurogenesis (Austin) 3:e1256853.

Rusnacu G (2016) Adult spinal cord neurogenesis: a regulator of nociception. Neurogenesis (Austin) 3:e1256853.

Zhang XL, Ding HH, Xu T, Liu M, Ma C, Wu SL, Wei JY, Liu CC, Zhang SR, Xin WJ (2018) Palmitoylation of delta-catenin promotes kinesin-mediated membrane trafficking of Nav1.6 in sensory neurons to promote neuropathic pain. Sci Signal 11:eaar4394.